UCLA Gets $1.14 Billion For Rights To Cancer Drug
socalTECH
MARCH 4, 2016
The University of California, Los Angeles (UCLA) has sold the royalty rights to a prostate cancer medication based on research done at the school, for a cool $1.14 According to UCLA, it sold its royalty interest connected with prostate cancer medication Xtandi to Royalty Pharma , which includes cash payments of $1.14 READ MORE>>.
Let's personalize your content